by Dale Harrison | Dec 1, 2022 | Press Releases
bioAffinity reports on a potential therapeutic approach that kills cancer cells without harm to normal cells SAN ANTONIO, TX – Dec. 1, 2022 – bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive diagnosis of...
by Dale Harrison | Nov 14, 2022 | Press Releases
SAN ANTONIO–(BUSINESS WIRE)– bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment, today reported its...
by Dale Harrison | Nov 10, 2022 | Press Releases
SAN ANTONIO–(BUSINESS WIRE)– bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) announced Sheila Habib, MD, Director of Pulmonary Lung Nodule Clinic and the Lung Cancer Screening Program at the South Texas Veterans Health Care Systems’ Audie L. Murphy...
by Dale Harrison | Nov 8, 2022 | Press Releases
SAN ANTONIO–(BUSINESS WIRE)– bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced that the Company will host a conference call and audio webcast on Monday, Nov. 14, 2022, at 8 a.m. ET to discuss its corporate and financial results for the...
by Dale Harrison | Oct 25, 2022 | Press Releases
Awarded patents protect novel porphyrin-conjugated compounds for selective delivery of cancer treatments SAN ANTONIO, TX – Oct. 25, 2022 – bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) announced the People’s Republic of China awarded a Certificate of Patent to...
by Dale Harrison | Oct 12, 2022 | Press Releases
Powerful platform reveals the lung environment for diagnosing lung diseases SAN ANTONIO, TX – Oct. 12, 2022 – bioAffinity Technologies, Inc., (NASDAQ: BIAF; BIAFW) will present results of its research into the use of flow cytometry for analyzing the lung environment...
